Irinotecan Amarox (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cells to SN‑38, a potent inhibitor of the enzyme topoisomerase I. By stabilising the DNA‑topoisomerase I complex, SN‑38 prevents the religation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately causing cancer cell death.

The dosing of Irinotecan Amarox is individualized by the prescribing oncologist. Factors such as body surface area, disease stage, prior therapies, and the patient’s hematologic and hepatic status are taken into account. The prescriber determines the exact amount, schedule, and any necessary dose adjustments.

Safety of Irinotecan in pregnancy and lactation has not been established. Because the drug can cross the placenta and is excreted in breast milk, it is generally avoided unless the potential benefit justifies the potential risk. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Irinotecan Amarox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, oncology centres, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, whereas other common agents such as oxaliplatin are platinum‑based DNA cross‑linkers. Irinotecan is often combined with fluoropyrimidines and can be effective after failure of oxaliplatin‑based regimens. The choice between agents depends on prior therapy, toxicity profile, and individual patient factors.

Irinotecan Amarox should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Before administration, allow the product to reach room temperature if required by the preparation protocol.

Irinotecan Amarox is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescribing physician and may be adjusted based on patient tolerance and concurrent medications. It is typically administered in a clinical setting equipped for monitoring adverse reactions.

The most serious risks include severe neutropenia that can lead to infection, febrile neutropenia, and life‑threatening diarrhea or colitis. Hepatic toxicity, allergic reactions such as anaphylaxis, and rare pulmonary complications like interstitial pneumonitis have also been reported. Prompt medical attention is required if any of these events occur.

Irinotecan should be avoided in patients with known hypersensitivity to irinotecan or any of its excipients, in those with severe hepatic impairment, and in individuals with uncontrolled infections. Caution is also advised for patients with a history of severe gastrointestinal disorders or significant bone‑marrow suppression.